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 Abstract
Lichen sclerosus is a chronic inflammatory skin disorder that belongs to a group of autoimmune connective tissue 
diseases, localized within the skin and mucous membrane of the anogenital area. In the latter location, the focal 
atrophy of the mucosa is the most visible sign. Lesions may be accompanied by symptoms such as itching, pain, 
burning. The disease occurs more often in females. The etiology is not fully understood. Genetic, infectious, hormonal 
factors and autoimmune mechanisms are taken into consideration. Early diagnosis and appropriate treatment is 
important to avoid further complications. This review aims to analyze available literature on the treatment of this 
disease entity.
 Key words: lichen sclerosus / genital organs / treatment /  
 Streszczenie
Liszaj twardzinowy jest przewlekłą chorobą zapalną należącą do grupy autoimmunologicznych chorób tkanki łącznej, 
lokalizującą się w obrębie skóry, oraz błon śluzowych narządów płciowych. W zakresie tej ostatniej lokalizacji, klinicznie 
obserwuje się najczęściej występowanie ogniskowego zaniku błony śluzowej. Wykwitom mogą towarzyszyć objawy 
subiektywne jak świąd, ból, pieczenie. Schorzenie zdecydowanie częściej występuje u płci żeńskiej. Etiologia nie 
jest do końca poznana. Pod uwagę bierze się rolę czynników genetycznych, autoimmunologicznych, infekcyjnych, 
hormonalnych. Ważne jest wczesne rozpoznanie choroby i włączenie odpowiedniego leczenia, celem uniknięcia 
powikłań. W pracy przeprowadzono analizę dostępnego piśmiennictwa dotyczącego leczenia tej jednostki 
chorobowej.
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Lichen	sclerosus	(lichen	sclerosus,	LS)	is	a	chronic	disease	
occurring	mainly	in	women.	The	disorder	has	two	peak	ages	of	
presentation:	in	the	fifth	and	sixth	decade	of	life	and	in	the	pre-
puberty	period	 [1].	 It	occurs	 less	often	 in Black	ethnic	groups.	
The	entity	was	first	described	by	Hallopeau	 in	1889,	while	 the	
historical	description	was	reported	in	1892	by	Darier	[2].	Due	to	
the	interdisciplinary	nature	of	the	disease,	the	exact	incidence	of	
the	disease	is	unclear.	It	is	estimated	that	in	the	general	population	
the	incidence	is	1:300	(0.03%)	to	1:1000	(0.1%).	It	occurs	much	
more	frequently	in	females,	except	during	the	pre-puberty	period	
[3].
Lesions	can	occur	in	any	location,	but	mostly	affect	the	side	
surfaces	of	the	neck,	the	collarbone	area,	arms,	anterior	surface	
of	 the	chest,	 sub	mammary	 regions	and	 the	flexion	surfaces	of	
the	 forearms.	 Typical	 lesions	 are	 porcelain-white	 papules	 that	
coalesce	into	larger	plaques	with	the	diameter	of	approximately	
1	cm2.	A	lilac	ring	may	also	be	an	additional	sign.	Older	lesions	
are	atrophied.	Cases	of epidermolysis	in	the	bladder	region	have	
been	reported	[4].	Few	cases	of	nails	and	oral	mucous	membrane	
involvement	have	been	reported	in	literature	as	well	[5].
The	lesions	may	also	affect	the	anogenital	area.	It	is	estimated	
that	LS	is	the	most	common	non-cancerous	disease	of	the	vulva	
epithelial. Its	occurrence	is	estimated	at	1	 in	500	women	of	all	
ages,	approximately	[2].	The	lesions	occur	within	the	labia	majora	
and	minora,	clitoris	and	the	anal	area.	LS	is	initially	characterized	
by	swelling	of	the	vulva,	which	later	transforms	into	a	hardening	
associated	with	chronic	inflammation.	The	elasticity	of	the	skin	
decreases;	 labia	 minora	 and	 the	 clitoris	 recede.	 The	 lesions	
generally	become	white	in	color.	As	a	result,	gradual	decay	and	
accompanying	 scarring	 may	 lead	 to	 adhesions	 and	 strictures,	
causing	 dysuria	 and	 dyspareunia.	 Patients,	 especially	 elderly	
women,	may	have	additional	visible	cracks,	rifts,	telangiectasia	
and	bleeding.	There	is	a	condition	known	as	perianal	pyramidal	
protrusion,	which	is	a	variant	of	LS,	occurring	in	female	infants,	
consisting	of	lumps	in	between	the	crotch	and	the perianal	area	
[6].	Erosions	and	ecchymosis	in	minors	may	be	mistaken	as	the	
evidence	of	 sexual	 abuse.	Lesions	 are	 accompanied	by	 intense	
itching	 and	 pain.	 These	 are	 the	 most	 common	 reasons	 why	
patients	seek	medical	advice	[3].
The	 diagnosis	 in	most	 patients	 is	 usually	made	 clinically,	
but	a	confirmatory	biopsy	remains	a	gold	standard	in	cases	with	
clinical	 doubt.	 It	 is	 helpful	 to	 exclude	 precancerous	 changes	
and	 cancer.	 Histological	 features	 include	 a	 thinned	 epidermis	
with	 focal	 hyperkeratosis,	 lymphocytic	 infiltrate	 and	 extended	
hyalinization	 in	 the	 upper	 dermis,	 homogenization	 of	 collagen	
and	arteritis	obliterans	[7].
The	etiology	of	the	disease	remains	unknown.	Genetic	factors	
are	thought	to	play	a	part	in	the	development	of	the	disease	due	to	
the	presence	of	family	cases,	as	well	as	determination	of	specific	
histocompatibility	 antigen	HLA	 class	 II.	 HLA	DQ7	 antigen	 is	
found	more	often	in	girls	and	adult	females	with	LS	than	in	the	
control	group.	It	seems	that	the	immunological	mechanisms	play	
an	important	role	in	the	pathogenesis	of	LS.	A	higher	incidence	
of	other	autoimmune	diseases	such	as	diabetes,	Graves-Basedow	
disease	and	alopecia	areata	has	been	reported	in	LS	patients	and	
their	 families.	Autoimmune	background	of	 the	 disease	may	be	
confirmed	by	the	detection	of	circulating	autoantibodies	against	
extracellular	 matrix	 protein	 type	 1	 or	 by	 targeting	 one	 of	 the	
pemphigoid	antigens	–	BP	180,	in	the	serum	of	patients	with	LS	
[8].	Since	1987,	 infectious	agents	such	as	Borrelia	burgdorferi,	
Borrelia	 garinii	 and	 Borrelia	 afzelii	 were	 considered	 to	 be	 a	
factor	 in	 the	 pathogenesis	 of	 localized	 scleroderma	 and	 LS.	
However,	consistent	data	has	not	fully	confirmed	the	spirochete	
as	a	causative	agent	but	since	treatment	with	antibiotics	such	as	
penicillin	and	cephalosporin	brings	good	results,	this	remains	a	
matter	of	interest.	The	importance	of	hormonal	factors	was	also	
not	clearly	explained.	The	disease	has	not	been	associated	with	
pregnancy,	hysterectomy,	contraceptive	or	hormone	replacement	
therapy	 although	 higher	 incidence	 of	 LS	 is	 observed	 in	 the	
group	 of	 postmenopausal	 women	 and	 prepubescent	 girls	 [3].	
Interestingly,	 in	the	latter	spontaneous	remission	is	seen	during	
adolescence.	 The	 regression	 of	 the	 anogenital	 area	 lesions	 is	
observed	in	an	approximately	6%	of	females	[9].
External	 factors	 play	 a	 role	 in	 the	 pathogenesis	 [10].	
Chronic	stimulation	is	thought	to	be	a	factor	predisposing	to	the	
development	of	squamous	cell	carcinoma	on	the	background	of	
LS	[11,	12].	Some	authors	suggest	that	LS	is	a	special,	superficial	
form	of	localized	scleroderma.	A	similarity	of	LS	and	lichen	planus,	
especially	with	regard	to	location,	including	genital	mucosa,	has	
also	been	suggested	[13,	14].	However,	LS	distinct	histological	
picture,	 including	 thinning	 live	 layers	 of	 the	 epidermis	 and	
degradation	of	the	elastic	fibers,	are	the	distinguishing	features.	
Additionally,	in	contrast	to	localized	scleroderma,	the	continuity	
of	the	basement	membrane	is	not	maintained	in	LS	[15].
The	aim	of	the	treatment	is	to	reduce	inflammation,	prevent	
the	formation	of	anatomical	abnormalities	and	the	development	
of	 malignant	 changes.	 Unfortunately,	 there	 is	 no	 effective	
therapy	 for	 LS.	 Potent	 or	 very	 potent	 topical corticosteroids 
(GKS) continue	to	occupy	a	prominent	place	in	local	therapy	and	
remain	 the	first-line	 treatment.	 In	many	studies,	 the	 topical	use	
of	potent	GKS,	 such	as	clobetasol	propionate,	proved	 to	be	an	
effective	treatment	for	LS	in	the	clinical	assessment.	In	the	study	
of	Bracco	et	al.,	it	was	more	effective	than	a	placebo	and	there	
were	 no	 adverse	 effects	 (i.e.	 infection,	 progression	 of	 atrophy,	
contact	dermatitis)	[16].	Furthermore,	there	was	also	a	significant	
improvement	in	histological	examination,	including	the	reduction	
of	inflammation	[17].	In	turn,	men	were	tested	using	mometasone,	
which	proved	 to	be	more	 effective	 than	a	placebo,	 too.	 In	 this	
study,	mometasone	was	used	at	a	concentration	of	0.05%,	while	
the	commercially	available	one	contains	a	concentration	of	0.1%,	
which	may	signify	that	the	effectiveness	of	the	drug	in	the	study	
was	actually	underestimated	[18].	
British	 Association	 of	 Dermatology	 Guidelines	 for	 the	
management	 of	 the	 disease	 recommend	 the	 use	 of	 very	 potent	
GKS	in	ointments	or	creams	as	first-line	therapy	[19].	Powell	et	
al.,	recommend	starting	therapy	using	clobetasol	at	a	concentration	
of	0.05%	twice	a	day	for	1	month	and	to	continue	treatment	for	
another	2	months	with	one	application	in	 the	evening.	In	order	
to	 avoid	 recurrence	 of	 the	 lesions,	 it	 is	 recommended	 to	 use	
potent	steroids	1-2	times	per	week	[20].	Lagos	et	al.	propose	to	
start	the	treatment	with	the	application	of	clobetasol	every	night	
for	one	month,	 then	every	other	day	 for	 another	month.	 In	 the	
third	month,	 the	 authors	 recommend	 the	 use	 of	 the	 product	 2	
times	a	week.	In	case	of	recurrence	of	the	lesions	it	is	proposed	
to	 return	 to	 the	 previous	 scheme	 at	 which	 improvement	 of	
the	 dermatological	 status	 was	 observed	 [21].	 Based	 on	 the	
evaluation	of	clinical	symptoms,	improvement	in	skin	condition	
and	 reduction	 of	 subjective	 symptoms	 were	 seen	 after	 topical	
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tramcinolon	 application	 [22].	 Quick	 resolution	 of	 the	 lesions	
is	 observed	 after	 an	 intralesional	 injection	 of	 tramcinolon	 at	 a	
concentration	of	2.5-5	mg/ml.	Local	anesthetics	are	used	in	these	
cases.	Such	injections	are	often	burdened	with	the	possibility	of	
adverse	 events,	 particularly	 the	 severity	 of	 an	 existing	 atrophy	
[23,	24].	
An	 alternative	 treatment	 for	GKS	 are	 topical calcineurin 
inhibitors.	A	study	conducted	by	a	Korean	team	has	shown	high	
efficacy	and	safety	of	topical	tacrolimus,	used	twice	a	day,	in	the	
long-term	therapy	of	LS	[25,	26].	In	another	study,	pimecrolimus,	
which	 proved	 to	 be	 equally	 effective,	 has	 been	 applied	 for	
two	 months.	 The	 majority	 of	 patients	 had	 partial	 or	 complete	
resolution	 of	 symptoms.	Additionally,	 histological	 examination	
showed	a	decrease	in	inflammatory	infiltration	and	expression	of	
molecules	CD3	(+),	CD8	(+),	CD57	(+)	T	cells	[27].	Subsequent	
studies	have	shown	an	increased	expression	of	p53	and	reduction	
of	 protein	Bcl	 -	 2	 particles	 in	 the	 keratinocytes	 of	 basal	 layer	
during	pimecrolimus	 treatment	 [28].	Goldstein	et	 al.	 compared	
the	clinical	efficacy	of	pimecrolimus	and	clobetasol	propionate	
and	found	no	differences	in	this	respect.	It	should	be	noted	that	
in	that	study	clobetasol	was	used	only	once	a	day.	Moreover,	the	
histological	 examination	 showed	 favorable	 results	with	 respect	
to	 clobetasol	 rather	 than	pimecrolimus.	There	were	no	adverse	
effects	of	the	above-mentioned	drugs	[29].	
It	is	worth	noting	that	pimecrolimus	is	a	substance	approved	
for	use	in	atopic	dermatitis	and	its	recommendation	to	a	patient	
with	LS	is	an	off	label	procedure.	One	should	always	bear	in	mind	
the	 contraindications	 for	 the	 use	 of	 immunosuppressive	 drugs	
in	 patients	 with	 LS	 co-infected	 with	 Human	 Papilloma	 Virus	
(HPV),	due	to	an	increased	risk	of	developing	malignancies	[30,	
31].	Especially	 since	 studies	 on	 the	 effectiveness	of	 individual	
drugs	in	the	LS	include	periods	not	longer	than	one	year,	which	
is	 undoubtedly	 an	 insufficient	 amount	 of	 time	 to	 evaluate	
future	 adverse	 effects.	Drugs	 derived	 from	 vitamin	A,	 such	 as	
isotretynoin,	may	be	used	in	cases	when	other	topical	treatments	
have	no	effect,	but	skin	irritation	may	limit	their	use	[32,	33].	
In	the	past	it	was	recommended	to	use	ointments	and	creams	
containing	hormones:	 testosterone,	progesterone,	 estrogen,	but	
the	effects	were	not	satisfactory.	Testosterone	ointment	showed	
efficacy	of	the	placebo	[16].	In	addition,	topical	testosterone	can	
lead	to	virilization	[34].
Taking	 into	 account	 the	 unknown	 infectious	 agent	 in	 the	
pathogenesis	of	LS,	 the	possibility	of	 using	antibiotics	 should	
be	 mentioned.	 The	 results	 show	 some	 efficacy	 of	 penicillins 
and	cephalosporins.	An	improvement	in	the	clinical	status	and	
reduction	of	symptoms	after	using	these	drugs	in	intramuscular	
injection	or	 by	oral	 administration	was	 noted.	However,	 blind, 
randomized	 studies	 and	controlled	 trials	were	never	performed	
[35].	 Another	 drug	 that	 tends	 to	 be	 effective	 is	 acitretin,	 a	
synthetic	analogue	of	retinoic	acid	which	reduces	hyperkeratosis	
and	normalizes	the	renewal	and	differentiation	of	epidermal	cells.	
Taking	20-30	mg	of	the	drug	daily	for	16	weeks	has	been	proven	
to	significantly	improve	the	clinical	status	of	patients.	The	study	
made	no	placebo	control	[32].	
According	to	Baskan	et	al.	the	use	of	medium	doses	(3-4	mg/
kg)	of	cyclosporin	for	3	months	offers	an	alternative	for	resistant	
LS.	After	 the	 therapy,	 clinical	 improvement	 was	 observed	 but	
histological	 examination	was	not	performed	due	 to	 the	 lack	of	
consent	from	the	patients	[36].	
In	 2002,	 reports	 were	 published	 on	 the	 efficacy	 of	 UVA	
phototherapy	 using	 a	 cream	 with	 psoralens	 in	 patients	 with	
inflammatory	diseases	of	the	anogenital	area,	including	the	LS.	
Most	 patients	 showed	 improvement	 in	 the	 clinical	 status	 and	
reduction	 in	 itching.	 However,	 the	 potential	 increased	 risk	 of	
malignancies	may	limit	its	use	[37].	There	are	also	isolated	reports	
of	successful	therapies	with	stanazol,	hydroxychloroquine,	and	
calcitriol,	which	also	did	not	include	the	placebo	group	[38,	39].
In	the	literature,	results	of	studies	evaluating	the	effectiveness	
of	 CO2 laser	 treatment	 have	 been	 found.	 Unfortunately,	 this	
method	 requires	 hospitalization	 and	 sometimes	 is	 performed	
under	 general	 anesthesia	 [40].	 Based	 on	 the	 results	 of	 clinical	
observations,	 a	 photodynamic therapy	 has	 proven	 to	 be	 an	
effective	 treatment	 in	 vulvar	 LS,	 especially	 when	 it	 comes	 to	
reduction	or	complete	relief	of	symptoms	reported	by	patients.	In	
addition,	immunohistochemical	and	histological	studies	showed	
a	 reduction	 in	 inflammatory	 infiltrate	 in	 the	 tissue	 [41,	 42].	
Eventually,	 if	 the	disease	has	a	 tendency	 to	progress	 and	 there	
is	 no	 response	 to	 treatment,	 surgical	 treatment	may	be	used	 to	
correct	anatomical	changes	caused	by	the	disease	[43].	However,	
it	should	be	noted	that	even	after	applying	surgical methods, a 
recurrence	is	observed	in	as	many	as	85%	of	cases	[44].
It	is	also	important	to	instruct	patients	about	proper	hygiene.	
Cleaning	agents	with	acidic	pH,	detergent-,	dye-	and	fragrance-
free,	 should	 be	 used.	 The	 anogenital	 area	 should	 be	 very	
thoroughly	dried.	Colored	and	perfumed	toilet	paper,	panty	liners	
and	 	 tampons	should	not	be	used.	Underwear	should	be	white,	
cotton	 and	 not	 too	 tight.	Also,	 patients	 should	 be	 discouraged	
from	mechanical	stimulation	of	the	affected	area,	such	as	shaving	
[45].
In	 case	 when	 the	 prescribed	 therapy	 fails,	 other	 factors	
such	as	coexisting	candidiasis	of	 the	vulva,	 incorrect	diagnosis	
(cancer,	 psoriasis,	 mucous	 membrane	 pemphigoid)	 and	 non-
compliance	(e.g.,	due	to	fear	of	adverse	reaction	of	GKS)	should	
be	considered	[34]).
Until	recently,	the	goal	of	the	LS	treatment	was	believed	to	be	
an	improvement	of	the	quality	of	life	for	the	patient	by	reducing	
the	 symptoms	 such	 as	 pain,	 itching	 and	 burning.	 Currently,	
an	 increased	 focus	 is	 put	 on	 the	 possibility	 of	 a	 malignant	
transformation.	The	risk	of	developing	squamous	cell	carcinoma	
(SCC)	 on	 the	 ground	 of	 LS	 ranges	 from	 4	 to	 5%,	 while	 the	
incidence	of	the	primary	SCC	in	the	UK	population	is	0.3%	[20,	
46].	There	are	also	descriptions	of	vulvar	verrucous	carcinoma	in	
women	with	LS	[47].	
The	 choice	 of	 the	 proper	 method	 of	 treatment	 continues	
to	present	 the	greatest	 challenge,	keeping	 in	mind	 that	 therapy	
can	 result	 in	an	uncontrolled	emergence	of	adverse	effects	and	
may	 intensify	 the	 existing	 disorders,	 including	 atrophy.	 Both	
gynecologists	 and	 dermatologists	 should	 be	 involved	 in	 the	
process	of	treatment,	as	sometimes	the	lesions	within	the	genital	
mucosa	 should	 be	 differentiated	 from	many	 other	 dermatoses.	
Topical,	potent	GKS	remain	the	first-line	treatment.	
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